MSTN and chronic obstructive pulmonary disease: Although it is known that Mstn inhibits PGC-1α and thus Fndc5 expression by activating p-Smad3 (Dong et al., 2016), the interaction between these two myokines in the pathogenesis of skeletal muscle dysfunction in COPD has not been reported.